← Chemomab Therapeutics Ltd. (CMMB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Chemomab Therapeutics Ltd. (CMMB)
Pharmaceutical Preparations · market cap $16M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Chemomab Therapeutics (CMMB) is a clinical-stage pharmaceutical company developing CM-101, an anti-CCL24 monoclonal antibody, in Phase 2 trials for Primary Sclerosing Cholangitis (PSC) and Nonalcoholic Steatohepatitis (NASH). The company completed an acquisition on 2026-07-08 and carries a ~$898M market cap against just $20.8M in cash, implying an extremely stretched valuation relative to its financial position. With only ~8.7 months of runway and no disclosed revenue, near-term dilution risk is the defining overhang.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | Phase 2 | Primary Sclerosing Cholangitis |
| 5 mg/kg CM-101 | Phase 2 | Nonalcoholic Steatohepatitis |
Price & technical context
3-month
-30.0%
6-month
-24.2%
12-month
-55.1%
52-wk range
$1.19–$3.50
vs 50-day MA
-43.8%
vs 200-day MA
-34.7%
Realized vol
97.8%
Max drawdown
-87.8%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CMMB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.